Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy.
Breccia
Massimo
M
Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy. breccia@bce.uniroma1.it
Cannella
Laura
L
Nanni
Mauro
M
Stefanizzi
Caterina
C
Alimena
Giuliana
G
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000235:genetics; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D010677:Philadelphia Chromosome; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines / Q000008:administration & dosage*; D012074:Remission Induction; D013844:Thiazoles; D013997:Time Factors
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; C498826:nilotinib; D000069439:Dasatinib